New hope for advanced breast cancer patients with specific gene mutation
NCT ID NCT04473040
First seen Jan 05, 2026
Summary
This program provides access to the drug alpelisib for adults with advanced hormone-positive, HER2-negative breast cancer that has a specific genetic mutation (PIK3CA) and has progressed after standard hormone therapy. It's designed for patients who meet specific health criteria and whose doctors agree to follow treatment guidelines. The goal is to control cancer growth in eligible patients when previous treatments have stopped working.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-world data may reveal true effectiveness of leading breast cancer therapy
- New drug combo shows promise for Hard-to-Treat breast cancer
- New pill combo aims to fight Hard-to-Treat breast cancer
- Real-world data on palbociclib combo for breast cancer in japan
- New pill shows promise against resistant cancers in early trial
- New study observes how palbociclib works in real life for breast cancer